Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
$57.34
$1.93(2.32%)
At close: 4:00 PM EST
$57.34
$1.93(2.32%)
Day’s Range― - ―
52-Week Range$43.08 - $93.80
Previous CloseN/A
Volume3.65M
Average Volume (3M)15.26M
Market Cap
$253.58B
Enterprise Value$257.56B
Total Cash (Recent Filing)$32.58B
Total Debt (Recent Filing)$101.21B
Price to Earnings (P/E)16.7
Beta1.15
Next Earnings
Feb 04, 2026EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend Yield3.58%
Share Statistics
EPS (TTM)0.69
Shares Outstanding3,390,128,000
10 Day Avg. Volume14,550,132
30 Day Avg. Volume15,261,671
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)19.23
Price to Sales (P/S)9.50
P/FCF Ratio39.62
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda1.57
Forecast
1Y Price Target
$54.67Price Target Upside-4.66% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAmycretin data showing competitive placebo-adjusted weight loss in both oral and subcutaneous arms supports product versatility and could broaden clinical adoption across different patient preferences.
Commercial AccessA discounted introductory self-pay offering together with a CVS Caremark exclusive distribution arrangement could expand patient access and accelerate adoption of obesity treatments.
Regulatory ApprovalFDA approval of an oral semaglutide formulation creates a first-mover advantage in oral dosing that could help regain incretin market share by attracting patients preferring pills over injections.
Bears Say
Clinical Program RiskDisappointing results in the EVOKE programs have weakened investor confidence and raise questions about the company's ability to sustain commercial momentum in the obesity portfolio.
Competitive PressureNext-generation oral GLP-1 products from competitors and compounded alternatives are eroding market share and may continue to siphon volume from the company's flagship treatments.
Pricing And MarginsOngoing net price declines, gross-to-net compression, and higher active ingredient costs could compress gross margins and weigh on revenue even if prescription demand remains resilient.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $43.08 and its highest was $93.80 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $253.58B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Feb 04, 2026 which is in 25 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Nov 05, 2025. The company reported $0.692 earnings per share for the quarter, missing the consensus estimate of $0.764 by -$0.072.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.412 which represents an annual dividend yield of 3.58%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.91.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.692 in its last earnings report, missing expectations of $0.764. Following the earnings report the stock price went up 0.435%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$54.67 (-4.66% Downside)
$54.67 (-4.66% Downside)
Blogger Sentiment
Bullish
NVO Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.70%
12-Months-Change
Fundamentals
Return on Equity
68.30%
Trailing 12-Months
Asset Growth
35.53%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NVO Company Deck
NVO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in sales and continued expansion in obesity care, supported by strategic acquisitions. However, significant challenges remain, including market share loss, restructuring efforts, and pricing pressures.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$54.67
▼(-4.66% Downside)
Technical Analysis
Ownership Overview
―
Insiders
1.32% Mutual Funds
4.01% Other Institutional Investors
94.48% Public Companies and Individual Investors